GCM
KYTX icon

Ghisallo Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Ghisallo Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,000
Closed -$300K – 179
2024
Q2 		$300K Hold
40,000
– – 0.03% 115
2024
Q1 		$994K Buy
+40,000
New +$1.12M 0.11% 102

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ghisallo Capital Management's KYTX Position: Q3 2024 in Review

Ghisallo Capital Management sold out of Kyverna Therapeutics (KYTX) in Q3 2024, closing a stake of 40,000 shares — an estimated $300K sold.

Ghisallo Capital Management first reported a position in KYTX in Q1 2024 and held it in 2 quarters. The position peaked at $994K in Q1 2024. 94 funds tracked by Wall St. Rank hold KYTX as of Q3 2024.

  • Ghisallo Capital Management reported no remaining Kyverna Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ghisallo Capital Management sold 40,000 Kyverna Therapeutics shares in Q3 2024, an estimated $300K.
  • Ghisallo Capital Management first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 2 quarters.
  • Ghisallo Capital Management's Kyverna Therapeutics position peaked at $994K in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2024.

Based on Ghisallo Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.